Predictive Biomarkers for Treatment Response for Head and Neck Cancers
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (28 February 2022) | Viewed by 8324
Special Issue Editor
Special Issue Information
Dear Colleagues,
Head and neck cancer squamous cell carcinoma (HNSCC) is a heterogeneous disease originating from the epithelial cell layer of the upper aerodigestive tract. These epithelial tumors are caused by multiple genetic alterations and are the seventh most common type of cancer worldwide. Head and neck cancer treatments often require different combinations of chemotherapy (mostly including cisplatin), surgery, and radiotherapy, but treatment resistance and local recurrence are still significant problems. In recent years, inhibition of EGFR signaling with the monoclonal EGFR antibody cetuximab (Erbitux®, Merck KGaA) and checkpoint inhibitors has emerged as a new treatment strategy, but only less than one third of unselected patients respond to new combination therapies. Therefore, to significantly increase overall survival in HNSCC patients, personalized targeted therapy is required, which depends on the establishment of novel biomarkers that can predict treatment response.
This Special Issue aims to consolidate the bench-to-bedside journey for developing new predictive biomarkers for treatment response in HNSCC and their significance for clinical decision. We welcome submissions that will contribute with biomarkers/a panel of biomarkers that could be used in the clinic for a more personalized treatment.
Prof. Dr. Karin Roberg
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Head and neck squamous cell carcinoma
- Predictive biomarkers
- Radiotherapy
- Chemotherapy
- Targeted therapy
- Immunotherapy
- Human papilloma virus
- Tumor microenvironment
- Cancer stem cells
- Hypoxia
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue polices can be found here.